(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which Exhibition hall Do You Suggest? Vote - 2Windows to the Previous: An Excursion Through the World's Notable Engineering
- 3Nitty gritty Manual for Picking Agreeable Tennis shoes
- 4NASA launches science balloon in Antarctica | Space photo of the day for Dec. 22, 2025
- 55 Great Youngster Care Administrations To Watch in 2024
- Emotional wellness Matters: My Fight with Tension
- RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
- The Best Internet based Courses for Expertise Improvement
- Vote in favor of your Number one Kind of Shades
- Former GLP-1 users regain lost weight after about 18 months, study says
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- The Best Web-based Courses for Ability Advancement
- As nations push for more ambition at climate talks, chairman says they may get it
